Trials / Completed
CompletedNCT01890655
Extension Study of MT-1303
A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-1303-Low | |
| DRUG | MT-1303-Middle | |
| DRUG | MT-1303-High |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2013-07-02
- Last updated
- 2016-04-11
Locations
17 sites across 17 countries: Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russia, Serbia, Spain, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01890655. Inclusion in this directory is not an endorsement.